China’s Two-Invoice Policy Will Significantly Change the Pharmaceutical Industry
Historically, there have been multiple invoices at different levels for selling drugs in China. Such multiple invoices have led to big mark-ups and some dishonest behavior in the marketplace. Thus, in mid 2016, the Chinese government released Circular 26, detailing plans to... Read More